Factors involved in treatment preference in patients with renal cancer: pazopanib versus sunitinib

Overview of attention for article published in Patient preference and adherence, April 2014

Altmetric Badge

Mentioned by

twitter: 2 X users

Citations

dimensions_citation: 5 Dimensions

Readers on

mendeley: 20 Mendeley

Summary X Dimensions citations

So far, Dimensions has found 5 publications that cite this research output.

5

The most recent citing publications are shown below. View all 5 publications that cite this research output on Dimensions.

Drug tolerability: How much ambiguity can be tolerated? A systematic review of the assessment of tolerability in clinical studies

Article in British Journal of Clinical Pharmacology (August 2021)

Pazopanib: Evidence review and clinical practice in the management of advanced renal cell carcinoma

Article in BMC Pharmacology and Toxicology (November 2018)

Real-World Treatment Patterns and Costs for Patients with Renal Cell Carcinoma Initiating Treatment with Sunitinib and Pazopanib

Article in Journal of Managed Care & Specialty Pharmacy (August 2016)